Diem, Lara; Chan, Andrew (2021). Persisting lymphopenia and dimethyl fumarate: A clinical commentary. Multiple sclerosis journal, 27(8), pp. 1309-1310. Sage 10.1177/1352458521996698
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Diem__2021__Persisting_lymphopenia_and_dimethyl_fumarate.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Author holds Copyright Download (81kB) | Request a copy |
Severe prolonged lymphopenia as rare side-effect of dimethyl fumarate is mostly reversible. Caldito et al. report a case of persistent severe lymphopenia over 5 years after discontinuation of dimethyl fumarate. We discuss several clinical implications. Safe withdrawal of disease modifying therapies in terms of reoccurrence of disease activity and drug related adverse events need further attention as our treatment armamentarium continues to grow.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Diem, Lara, Chan, Andrew Hao-Kuang |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1352-4585 |
Publisher: |
Sage |
Language: |
English |
Submitter: |
Chantal Kottler |
Date Deposited: |
12 Jul 2021 15:47 |
Last Modified: |
05 Dec 2022 15:51 |
Publisher DOI: |
10.1177/1352458521996698 |
PubMed ID: |
33620267 |
Uncontrolled Keywords: |
Lymphopenia case report dimethyl fumarate disease modifying therapies safety side effect |
BORIS DOI: |
10.48350/157354 |
URI: |
https://boris.unibe.ch/id/eprint/157354 |
Actions (login required)
 |
Edit item |